Aspira Pathlab & Diagnostics Ltd (ASPIRA) — shareholding pattern, promoter holding, financials and share price
About Aspira Pathlab & Diagnostics Ltd (ASPIRA)
Aspira Pathlab & Diagnostics Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as ASPIRA and on the BSE under scrip code 540788. Its ISIN is INE500C01017.
Incorporated in 1973, Aspira Pathlab & Diagnostics Ltd is in the business of pathology and related healthcare services [1]
Aspira Pathlab & Diagnostics Limited (ASDL) is a leading pathology specialist in India, offering a wide range of diagnostic services.
The company operates with an asset-light model but faces high operational costs which it is working to optimize.
Listed peers in Healthcare Service Provider: Star Imaging and Path Lab Ltd, Vijaypd Ceutical Ltd, Nephro Care India Ltd, Invicta Diagnostic Ltd, Choksi Laboratories Ltd, Modern Diagnostic & Research Centre Ltd.
Valuation & Returns
10 Jul 2026At ₹99.85 a share on 10 Jul 2026, Aspira Pathlab & Diagnostics Ltd (ASPIRA) was valued at a price-to-earnings ratio of 42.82x against an industry P/E of 61.73x and a price-to-book of 8.45x on a book value of ₹11.82 per share as of Mar 2025. Solomo computes return on equity of 19.73% and return on capital employed of 15.62% from filed results. Earnings ratios use consolidated results for the twelve months Sep 2024 to Jun 2025.
- P/E
- 42.82x
- Industry P/E
- 61.73x
- P/B
- 8.45x
- EPS (TTM)
- ₹2.33
- Book value / share
- ₹11.82
- ROE
- 19.73%
- ROCE
- 15.62%
- ROA
- 13.74%
- Debt / equity
- 0.26x
- Dividend yield
- 0%
- EBITDA margin
- 17.15%
- 52-week range
- ₹49 – ₹135.88
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2025In the year ended Mar 2025, Aspira Pathlab & Diagnostics Ltd (ASPIRA) reported revenue of ₹22 crore, net profit of ₹2.02 crore and earnings per share of ₹1.96. That compares with revenue of ₹13.2 crore and net profit of ₹-2.67 crore in Mar 2024. Figures are consolidated, as filed with the exchanges.
In the quarter ended Jun 2025, revenue was ₹5.25 crore and net profit ₹0.42 crore (consolidated).
| Metric | Mar 2024 | Mar 2025 |
|---|---|---|
| Revenue (₹ cr) | 13.2 | 22 |
| Net profit (₹ cr) | -2.67 | 2.02 |
| EPS (₹) | -2.59 | 1.96 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | - | 21.19% | 4.03% | 66.67% |
| Profit growth | 61.69% | - | -22.54% | 175.66% |
| Stock price CAGR | - | 20% | 48% | 71% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 46.58% of Aspira Pathlab & Diagnostics Ltd (ASPIRA) (up 28.19 pp QoQ). Market capitalisation was ₹103 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2017.
Largest disclosed public shareholders in Jun 2026: ADITYA AGRAWAL 7.39%, RAJESH PREMJI BHANUSHALI 5.52%, HUF 5.51%, PANKAJ JASHWANT SHAH 4.86%, POOJA RAJESH BHANUSHALI 3.6%, MANAS MODI 3.36%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 46.58% | - | - | - | 53.42% |
| Mar 2026 | 18.39% | - | - | - | 81.61% |
| Dec 2025 | 18.39% | - | - | - | 81.61% |
| Sep 2025 | 18.39% | - | - | - | 81.61% |
| Jun 2025 | 18.39% | - | - | - | 81.61% |
| Mar 2025 | 18.39% | - | - | - | 81.61% |
| Dec 2024 | 18.55% | - | - | - | 81.45% |
| Sep 2024 | 18.55% | - | - | - | 81.45% |